RIBOPRO Secures Series A Funding to Accelerate mRNA-Based technologies
RIBOPRO has successfully closed a Series A funding round. This funding will drive efforts to transform the industry with innovative mRNA and LNP technologies, providing a range of solutions to address current challenges within the field.
RIBOPRO announces groundbreaking research on antifibrotic effects of mRNA
RIBOPRO announces the publication of a new research article by López-Cerdá et al., titled “Antifibrotic and Pro-Regenerative Effects of SMAD3 siRNA and Collagen I mRNA Loaded Lipid.” This groundbreaking study utilized RIBOPRO’s off-the-shelf eGFP mRNA and custom mRNA to explore innovative methods for combating fibrosis and promoting tissue regeneration.
RIBOPRO, a leading biotechnology company dedicated to supporting biotech and biopharma in the co-creation of innovative mRNA medicines based on proprietary mRNA technologies and high-quality mRNA/LNP manufacturing, proudly announces the successful completion of a €1.9 million Convertible Loan Agreement (CLA) that marks a significant milestone in its growth trajectory.
Ardena and RiboPro Forge Strategic Alliance
Leading contract development manufacturer of nanomedicines, Ardena, has joined forces with mRNA and LNP technology specialists RiboPro to form a new strategic commercial alliance aimed at delivering improvements to the global availability of RNA-based health treatments and address a crucial skills gap in the industry.
CEO RiboPro elected most promising entrepreneur of the year.
Sander van Asbeck, CEO and co-founder of RiboPro has been elected most promising entrepreneur of the year 2022. With his company, he develops messenger RNA technology for the development of new medical treatments.
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.
